Olympus Corporation
7733.T · JPX
Company research
Olympus Corporation (7733.T) is a globally recognized Japanese MedTech enterprise headquartered in Tokyo, Japan, originally founded in 1919 as Takachiho Seisakusho and listed on the Tokyo Stock Exchange. The company specializes in the manufacture and sale of precision medical devices and instruments, with operations structured across key segments including Endoscopic Solutions, Therapeutic Solutions, Scientific Solutions, and Others, with endoscopic solutions accounting for more than 60% of its revenue as of March 2025. Its product portfolio spans gastrointestinal and surgical endoscopes, urology, gynecology, ENT and respiratory therapeutic devices, biological and industrial microscopes, non-destructive testing equipment, and XRF analyzers, supported by system integration and maintenance services. With approximately 30,000 employees operating across nearly 40 countries, Olympus holds a leading global market position in endoscopy, with North America representing its largest regional revenue contributor at approximately 38% of total revenue.
Research reports
Platform-generated equity research-style overview that models Olympus’ intrinsic value and finds the shares modestly undervalued versus fair value, with forecasts of double‑digit annual earnings growth, detailed profitability and balance-sheet metrics, peer comparisons, and explicit discussion of risks such as margin compression, dividend coverage, product issues, and share-price volatility relative to the Japanese medical equipment industry and wider market.
Investing.com · May 11, 2026Olympus FY2026 slides: FDA impact absorbed, margin...Earnings-analysis article reviewing FY2026 as a “rebuilding year” that absorbed roughly ¥30 billion in FDA-related impacts, quantifying full-year and Q4 revenue, margin compression and recovery, and FY2027 guidance for revenue, margin expansion and EPS growth, while highlighting capital-allocation changes toward buybacks, divisional performance (GIS vs. SIS), quality remediation efforts, and ongoing execution, regulatory and portfolio-review risks that may constrain the pace of recovery.
AlphaBond (Buttondown Newsletter) · October 6, 2025Alpha Signal: Olympus Corporation (7733.T) Price Surge 5.7%Signal note for bond and equity desks analyzing a 5.7% intraday price spike in Olympus, concluding that no time-aligned company, exchange or major wire disclosure explains the move, and therefore recommending a hold/monitor stance on bonds while summarizing recent share-repurchase activity, ratings and bond profile, market context, and a set of risks to track including future TDnet/IR filings, rating-agency actions, short-interest dynamics and potential block trades.